Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-CD19-CAR-CD28-IL-15-expressing natural killer T cells

A preparation of allogeneic natural killer T lymphocytes (NKTs) that have been engineered to express a chimeric antigen receptor (CAR) specific for the human tumor associated antigen (TAA) CD19, interleukin 15 (IL-15) and the costimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD19-CAR-CD28-IL-15-expressing NKTs target, bind to, and induce selective toxicity in CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that promotes T-cell persistence and potentiates the immune response against tumor cells. CD28 costimulatory molecule enhances activation and signaling after recognition of CD19, and may increase proliferation of T cells and antitumor activity. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.
Synonym:allogeneic anti-CD19 CAR/IL-15-expressing natural killer T cells
allogeneic anti-CD19-CAR-CD28-IL-15-expressing NKTs
allogeneic anti-CD19-CAR-IL-15-expressing natural killer T cells
CD19.CAR allogeneic NKT cells
CD19.CAR-aNKT cells
CD19.CAR-aNKTs
Search NCI's Drug Dictionary